[Federal Register Volume 62, Number 206 (Friday, October 24, 1997)]
[Notices]
[Pages 55408-55409]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-28225]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 97N-0424]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on a proposed revision of the form for
the collection of certain information by the agency. Under the
Paperwork Reduction Act of 1995 (the PRA), Federal agencies are
required to publish notice in the Federal Register concerning each
proposed collection of information and to allow 60 days for public
comment in response to the notice. This notice solicits comments on a
revised, harmonized transmittal form, ``Transmittal of Advertisements
and Promotional Labeling for Drugs and Biologics for Human Use'' (Form
FDA 2253). This revised and harmonized form will be used for the
submission of advertisements and promotional labeling for prescription
drugs, antibiotics, and biological products that are regulated by the
Center for Drug Evaluation and Research (CDER) and the Center for
Biologics Evaluation and Research (CBER).
DATES: Submit written comments on the collection of information by
December 23, 1997.
ADDRESSES:
CDER Information: Submit written requests for single copies of the
revised, harmonized transmittal form, Form FDA 2253, to the Drug
Information Branch (HFD-210), Division of Communications Management,
Center for Drug Evaluation and Research, Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-594-1012. Send one self-
addressed adhesive label to assist that office in processing your
requests. The form may also be obtained by calling the CDER Fax-on-
Demand System at 1-800-342-2722 or 1-301-827-0577.
CBER Information: Submit written requests for single copies of the
revised, harmonized transmittal form, Form FDA 2253, to the Office of
Communications, Training, and Manufacturers Assistance (HFM-40), Center
for Biologics Evaluation and Research, Food and Drug Administration,
1401 Rockville Pike, Rockville, MD 20852-1448. Send one self-addressed
adhesive label to assist that office in processing your requests. The
form may also be obtained by calling the CBER Voice Information System
at 1-800-835-4709.
Submit written comments on the revised, harmonized transmittal
form, Form FDA 2253, and its proposed use in collection of information,
to the Dockets Management Branch (HFA-305), Food and Drug
Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Two
copies of any comments are to be submitted except that individuals may
submit one copy. Requests and comments should be identified with the
docket number found in brackets in the heading of this document. A copy
of the revised, harmonized transmittal form, Form FDA 2253, and
received comments are available for public examination in the Dockets
Management Branch (address above) between 9 a.m. and 4 p.m., Monday
through Friday.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information
Resources Management (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1472.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information listed below.
With respect to the following collection of information, FDA
invites comments on: (1) Whether the proposed collection of information
is necessary for the proper performance of FDA's functions, including
whether the information will have practical utility; (2) the accuracy
of FDA's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used;
[[Page 55409]]
(3) ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) ways to minimize the burden of the
collection of information on respondents, including through the use of
automated collection techniques, when appropriate, and other forms of
information technology.
Transmittal of Advertisements and Promotional Labeling for Drugs
and Biologics for Human Use (Form FDA 2253)
Under Sec. 314.81(b)(3)(i) (21 CFR 314.81(b)(3)(i)), sponsors of
approved applications for marketed prescription drugs and antibiotic
drugs for human use are required to submit specimens of promotional
labeling and advertisements at the time of initial dissemination of the
labeling and at the time of initial publication of the advertisement.
Each submission is required to be accompanied by a completed
transmittal Form FDA 2253 (Transmittal of Advertisements and
Promotional Labeling for Drugs for Human Use). Statutory authority for
the collection of this information is provided by sections 505(a), (b),
(j), and (k), 507(g), and 701(a) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(a), (b), (j), and (k), 357(g), and 371(a)).
Similarly, under Sec. 601.12(f)(4) (21 CFR 601.12(f)(4)) (62 FR
39890, July 24, 1997; effective October 7, 1997), manufacturers of
licensed biological products are required to submit specimens of
advertising and promotional labeling to FDA in accordance with
Sec. 314.81(b)(3)(i). Statutory authority for the collection of this
information is provided by section 351 of the Public Health Service Act
(42 U.S.C. 262), which gives FDA the responsibility to prescribe
standards designed to ensure the safety, purity, potency, and
effectiveness of biological products. In furtherance of this
responsibility, FDA regulates advertising and labeling for biological
products. Currently, specimens of advertising and promotional labeling
are submitted to FDA with Form FDA 2567, a two-part transmittal form
that is also used to transmit other forms of labeling (e.g., circulars,
package labels, and container labels) for FDA review when a firm is
requesting premarket approval of a product or proposing changes to
product carton or container labeling.
FDA is revising Form FDA 2253 to enable it to be used to transmit
specimens of promotional labeling and advertisements for biological
products as well as for prescription drugs and antibiotics. The
proposed revised form has the following major changes:
1. The revised, harmonized form will be used by sponsors of
approved applications for marketed prescription drugs and antibiotic
drugs regulated by CDER who must submit specimens of advertisements and
promotional labeling to the agency, and may be used by manufacturers of
licensed biological products regulated by CBER who submit draft and/or
final copies of promotional labeling and advertisements to the agency.
Revising and harmonizing Form FDA 2253 will eliminate the need for
sponsors to use two different forms to transmit similar materials for
submission to the agency; however, manufacturers of biological products
may continue to use Form FDA 2567 to transmit advertisements and
promotional labeling if they wish. The other uses of Form FDA 2567 will
remain unchanged.
2. The revised, harmonized form updates the information about the
types of promotional materials and the codes that are used to clarify
the type of advertisement or labeling submitted; clarifies the intended
audience for the advertisements or promotional labeling (e.g.,
consumers, professionals, news services); and helps ensure that the
submission is complete.
3. Currently, when more than one prescription drug product is
promoted in the promotional labeling or in an advertisement, sponsors
submit specimens of the promotional labeling or advertisement to the
approved application for each product promoted in the promotional
labeling or advertisement. The revised form provides for sponsors to
submit specimens of multi-product promotional labeling and
advertisements to only two files; to the approved product application
most frequently promoted, and to a company name file. This multi-
product submission should cross-reference the other approved
applications. The agency anticipates that the proposed revised form and
revised submission procedures will save sponsors time and money by
eliminating the need for making multiple submissions and for
maintaining dual inventories of both forms and multiple processing
capabilities.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden
------------------------------------------------------------------------
Total
Form No. of Total Annual Hours per Estimated
Respondents Responses Response Hours
------------------------------------------------------------------------
FDA 2253 612 12,379 2 24,758
------------------------------------------------------------------------
There are no capital costs or operating and maintenance costs associated
with this collection of information.
In FY 95, CDER received 10,879 submissions of advertising and
promotional labeling under Form FDA 2253 from an estimated 512
manufacturers. In the same period of time, CBER received 1,034
submissions from 57 manufacturers that could have made use of revised
Form FDA 2253. Prior to October 7, 1997, the submission of advertising
and promotional labeling to CBER using Form FDA 2567 was a voluntary
procedure. Under Sec. 601.12(f)(4) (62 FR 39890), manufacturers of
licensed biological products are required to submit specimens of
advertising and promotional labeling to FDA in accordance with
Sec. 314.81(b)(3)(i). FDA estimates that under the new regulation, CBER
will receive over 1,500 submissions from approximately 100
manufacturers that may use the revised Form FDA 2253. Thus, FDA
estimates that there may be 12,379 submissions of advertising and
promotional labeling to FDA under revised Form FDA 2253. Based on
contacts with industry representatives, FDA estimates that 2 hours
would be required for an industry regulatory affairs specialist to fill
out the proposed form, collate the documentation, and send the
submission to CDER or CBER. Manufacturers of biological products may
use the revised Form FDA 2253 or may continue to use Form FDA 2567 for
the submission of advertisements and promotional labeling to CBER.
Dated: October 17, 1997.
William K. Hubbard,
Associate Commissioner for Policy Coordination.
[FR Doc. 97-28225 Filed 10-23-97; 8:45 am]
BILLING CODE 4160-01-F